Forward PE Ratio: 36.89
The forward PE ratio is 36.89 as of Thursday, July 9, 2026.
Forward PE Ratio (36.89) = Close Price ($71.15) / Consensus Forward EPS ($1.92)
TECH Forward PE Ratio Metrics
FORWARD PE RATIO
36.89
TECH Competitors' Forward PE Ratio
Bio-Techne Corporation
Market Cap
$11.14B
Forward PE Ratio
36.89
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Bio-Techne Corporation (TECH) | $11.14B | 36.89 |
| Charles River Laboratories International, Inc. (CRL)vs › | $11.25B | 20.18 |
| Insulet Corp. (PODD)vs › | $10.96B | 24.29 |
| Tempus AI, Inc. (TEM)vs › | $10.73B | N/A |
| Baxter International Inc. (BAX)vs › | $11.60B | 11.45 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 7.65 |
| Molina Healthcare, Inc. (MOH)vs › | $12.09B | 45.00 |
| Universal Health Services, Inc. (UHS)vs › | $9.72B | 6.66 |
| Revvity, Inc. (RVTY)vs › | $12.60B | 20.86 |
| Henry Schein, Inc. (HSIC)vs › | $9.55B | 15.56 |
Trailing vs Forward
Trailing P/E
102.8
reported TTM EPS
Forward P/E
36.9
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.92 implies +178.3% EPS growth vs the reported trailing $0.69.
Forward P/E by Fiscal Year
View All Analyst EstimatesAt today's $71.15 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-06-30 | $2.05 | $1.95 – $2.16 | 8 | 34.7x |
| 2028-06-30 | $2.32 | $2.17 – $2.48 | 3 | 30.7x |
| 2029-06-30 | $2.67 | $2.63 – $2.73 | 1 | 26.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
Forward PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Forward PE Ratio FAQ
- What is the forward PE ratio for Bio-Techne Corporation (TECH)?
- The forward PE ratio for TECH stock is 36.89.
Related Metrics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman